Covaxin Safe, Phase 3 Results Needed: Lancet

Covaxin, the homegrown coronavirus vaccine that was authorised for use in January before full clinical trial data, has been declared "safe, immunogenic with no serious side effects" by Lancet that has published its Phase 2 results. Medical journal Lancet has said that efficacy cannot be determined by Phase 2 trials but the vaccine made by Hyderabad-based Bharat Biotech is "safe/immunogenic". The Lancet report says the results reported in the study of Phase 2 results do not permit efficacy assessments and further corroboration with Phase 3 safety results was required.